<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23289">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01792713</url>
  </required_header>
  <id_info>
    <org_study_id>E550-PRU-2012</org_study_id>
    <secondary_id>2012-003954-95</secondary_id>
    <nct_id>NCT01792713</nct_id>
  </id_info>
  <brief_title>Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis</brief_title>
  <official_title>Randomisierte, Doppelblinde, Plazebo-kontrollierte Prüfung Zum Nachweis Der Wirksamkeit Und Der Lokalen Verträglichkeit Einer 2%Igen Sertaconazol-Crème Bei Patienten Mit Atopischer Dermatitis (Abridged)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spirig Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spirig Pharma Ltd.</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation aimed to explore the efficacy of a topical Sertaconazole cream 2% in patients
      with skin alterations associated with atopic dermatitis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Patient Global Assessment (PGA)</measure>
    <time_frame>day 1, day 28</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>day 1, day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>d1, d28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Benefit Index (PBI)</measure>
    <time_frame>day 1, day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Transepidermal water loss (TEWL)</measure>
    <time_frame>d1, d14, d28, d42</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Skin Alterations Associated With Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Sertaconazole 2% cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2x daily treatment with Sertaconazole 2% cream for 4 weeks, 2 weeks follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2x daily treatment with Placebo cream for 4 weeks, 2 weeks follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertaconazole 2% cream</intervention_name>
    <arm_group_label>Sertaconazole 2% cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Atopic Dermatitis Patients with SCORing Atopic Dermatitis (SCORAD) ≤ 40

          -  Atopic lesion localisation: arms; additional legs, neck

        Exclusion Criteria:

          -  SCORAD &gt; 40

          -  Unstable, uncontrolled medical status (e.g. active systemic or topical infection)

          -  Active immunosuppression or cancer

          -  Narcotics- or Alcohol abuse

          -  Participation in another clinical trial until one month prior inclusion

          -  Known allergies against an ingredient of the investigational medicinal product

          -  Different periods of grace for certain pre-treatments, e.g. topical corticosteroids,
             immune modulating drugs

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mac Heynar Ramos Frisancho, Dr. med.</last_name>
    <phone>+41623878869</phone>
    <email>macheynar.ramos@spirig.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsmedizin Charité Berlin, Abteilung für Dermatologie und Allergologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Metz, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik für Hautkrankheiten</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 14, 2013</lastchanged_date>
  <firstreceived_date>February 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin alterations</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sertaconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
